HCPLive Network

FDA Bars Generic Version of Oxycontin

On April 16, 2013, the US Food and Drug Administration (FDA) announced that, “because original OxyContin provides the same therapeutic benefits as reformulated OxyContin, but poses an increased potential for certain types of abuse, the FDA has determined that the benefits of original OxyContin no longer outweigh its risks.” Noting that original OxyContin was “withdrawn from sale for reasons of safety or effectiveness,” the FDA announced that it “will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of original OxyContin.”
 
Simply put, the FDA has decided that generic forms of the original formulation of OxyContin will not be allowed in the US market, period. The original form of OxyContin has been replaced by reformulated OxyContin (OxyNEO in Canada). This will mean that “hardened” forms of oxycodone and other extended-release (ER) or long-acting (LA) opioids will likely be required to employ “safety” features to be sold in the US.
 
Attempts to bring lower-cost generics, or alternative forms of controlled-release oxycodone to the US market will require competing manufacturers to utilize safety mechanisms such as incorporating multiple polymers to prevent users from crushing the pills into a fine powder, adding components to create gelling if added to water, or employing an opioid antagonist or some type of irritant in the medication to make misuse or abuse a very unpleasant experience.
 
The April 16 FDA press release also recognized the changes made by Purdue Pharma to “harden” reformulated OxyContin, and granted permission for a label change indicating “the product has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route (snorting).” This is the first time the FDA has permitted a drug manufacturer to state that a narcotic medication has tamper-resistant properties.
 
Douglas Throckmorton, MD, deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research said, “The development of abuse-deterrent opioid analgesics is a public health priority for the FDA,” and that while “both original and reformulated OxyContin are subject to abuse and misuse, the FDA has determined that reformulated OxyContin can be expected to make abuse by injection difficult and [be] expected to reduce abuse by snorting compared to original OxyContin.”
 
It will be interesting to see whether the FDA makes a similar ruling regarding Endo Pharmaceuticals and Opana. The New York Times recently reported that Endo “has also petitioned the FDA seeking a similar claim of abuse resistance for a newer version of one of its drugs, Opana. If that claim proves successful, generic versions of the original form of Opana would also be barred.” The NYT article also stated that “Over the last year, Purdue Pharma and Endo have pushed for federal legislation that would require many opioids to be tamper-resistant, and lobbied in favor of similar state laws.”
 
This decision is likely to create pressure on all makers of ER/LA opioids to incorporate abuse-resistant or abuse-deterrent features in their medications. Currently, there is a four-year Risk Evaluation and Mitigation Strategy (REMS) effort to train 320,000 US prescribers to better screen and treat pain sufferers with opioid analgesics. Together, the new push for “hardened” medications and better prescribing practices may significantly reduce overdose deaths associated with opioid misuse and abuse.


B. Eliot Cole, MD, MPA, FAPA, CPE, is a member of the Pain Management editorial advisory board. He has served in executive positions for several prominent pain management organizations and societies, including the American Society of Pain Educators and the American Academy of Pain Management. He has been a pain management fellow, clinician, educator, and advocate for nearly 30 years and has practiced in a variety of settings serving a wide range of patients.

Further Reading
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.
Workplace flu shots are a good investment, a new survey found. The US Centers for Disease Control and Prevention (CDC) on Sept. 19 urged all health care personnel to get flu vaccinations. The CDC also released the results of a survey of 1,882 health care clinicians meant to determine what factors influenced those who got the shots. Among its findings, when workplaces offered free shots on-site, compliance was 61.6% when the vaccinations were offered for one day only. When they were offered for multiple days, compliance rose to 80.4%. When employers did not offer the shots at all, compliance dropped to 49.0%
Less than half of all Americans got a flu shot last year, so U.S. health officials on Thursday urged that everyone 6 months and older get vaccinated for the coming flu season. "It's really unfortunate that half of Americans are not getting the protection from flu they could get," said Thomas Frieden, MD, director of the U.S. Centers for Disease Control and Prevention, during a morning news conference.
Just a single dose of a common antidepressant can quickly alter the way brain cells communicate with one another, according to early research published online Sept. 18 in Current Biology.
Women who have the largest number of posttraumatic stress disorder symptoms are almost three times more likely to develop an addiction to food, according to a study published online Sept. 17 in JAMA Psychiatry.
The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.
Strategies are presented to help physicians lower their tax burden in an article published Sept. 2 in Medical Economics.
More Reading